natgillin/translations-raw huggingface dataset:
This means that Zoledronic acid Teva Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Aclasta.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Aclasta.
The European Commission granted a marketing authorisation valid throughout the European Union for Zoledronic acid Teva Pharma on 16 August 2012.
Evropska komisija je dovoljenje za promet z zdravilom Zoledronska kislina kislina Teva Pharma, veljavno po vsej Evropski uniji, izdala 16. avgusta 2012.
This leads to less bone loss in osteoporosis and less disease activity in Paget's disease.
Zaradi tega se pri osteoporozi zmanjša izguba kostne mase, pri Pagetovi bolezni pa se zmanjša dejavnost bolezni.
Because Zoledronic acid Teva Pharma is a generic, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Zoledronska kislina kislina Teva Pharma generično zdravilo, so koristi in tveganja enaki kot pri referenčnem zdravilu.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zoledronic acid Teva Pharma, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid Teva Pharma.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
In the treatment of Paget's disease of the bone, Zoledronic acid Teva Pharma must only be used by a doctor who has experience in the treatment of the disease.
Pri zdravljenju Pagetove bolezni kosti sme zdravilo Zoledronska kislina kislina Teva Pharma uporabljati samo zdravnik, ki ima izkušnje z zdravljenjem te bolezni.
What measures are being taken to ensure the safe and effective use of Zoledronic acid Teva Pharma?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovine uporabe zdravila Zoledronska kislina Teva Pharma?
Zoledronic acid Teva Pharma is given as an infusion lasting at least 15 minutes.
Zdravilo Zoledronska kislina kislina Teva Pharma se daje z infuzijo, ki traja najmanj 15 minut.
Zoledronic acid Teva Pharma is a solution for infusion (drip) into a vein that contains the active substance zoledronic acid (5 mg).
Zdravilo Zoledronska kislina kislina Teva Pharma je raztopina za infundiranje (kapalno infuzijo) v veno, ki vsebuje zdravilno učinkovino zoledronska kislina (5 mg).
Zoledronic acid Teva Pharma is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men.
Zdravilo Zoledronska kislina kislina Teva Pharma se uporablja za zdravljenje osteoporoze (bolezni, ki povzroča krhkost kosti) pri ženskah v obdobju po menopavzi in pri moških.
Patients who have broken their hip should not receive Zoledronic acid Teva Pharma any earlier than two weeks after the operation to repair the fracture.
Bolniki z zlomljenim kolkom lahko zdravilo Zoledronska kislina Teva Pharma prejmejo šele dva tedna po operaciji, da se zlom zaceli.
Therefore, the CHMP's view was that, as for Aclasta, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Aclasta, odtehtajo znana tveganja.
What are the benefits and risks of Zoledronic acid Teva Pharma?
Kakšne so koristi in tveganja, povezani z zdravilom Zoledronska kislina kislina Teva Pharma?
Other information about Zoledronic acid Teva Pharma
Druge informacije o zdravilu Zoledronska kislina Teva Pharma
The Committee recommended that Zoledronic acid Teva Pharma be given marketing authorisation.
Priporočil je, da se za zdravilo Zoledronska kislina kislina Teva Pharma izda dovoljenje za promet.
A risk management plan has been developed to ensure that Zoledronic acid Teva Pharma is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Zoledronska kislina Teva Pharma je bil pripravljen načrt obvladovanja tveganj.
Zoledronic acid Teva Pharma zoledronic acid
Zoledronska kislina Teva Pharma zoledronska kislina
Zoledronic acid Teva Pharma is a ‘generic medicine'.
Zdravilo Zoledronska kislina kislina Teva Pharma je „generično zdravilo“.
The active substance in Zoledronic acid Teva Pharma, zoledronic acid, is a bisphosphonate.
Zdravilna učinkovina zdravila Zoledronska kislina kislina Teva Pharma, zoledronska kislina, je difosfonat.
No additional studies were needed as Zoledronic acid Teva Pharma is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Aclasta.
Ker je zdravilo Zoledronska kislina kislina Teva Pharma generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Aclasta, niso bile potrebne nobene dodatne študije.
Why has Zoledronic acid Teva Pharma been approved?
Zakaj je bilo zdravilo Zoledronska kislina kislina Teva Pharma odobreno?
Zoledronic acid Teva Pharma is also used to treat Paget's disease of the bone in adults.
Zdravilo Zoledronska kislina kislina Teva Pharma se uporablja tudi za zdravljenje Pagetove bolezni kosti pri odraslih, tj. bolezni, pri kateri je normalen postopek rasti kosti spremenjen.
Zoledronic acid Teva Pharma should not be used in patients with severe kidney problems.
Bolniki s hudimi ledvičnimi težavami zdravila Zoledronska kislina kislina Teva Pharma ne smejo uporabljati.
What is Zoledronic acid Teva Pharma?
Kaj je zdravilo Zoledronska kislina Teva Pharma?
How does Zoledronic acid Teva Pharma work?
Kako zdravilo Zoledronska kislina kislina Teva Pharma deluje?
What is Zoledronic acid Teva Pharma used for?
Za kaj se zdravilo Zoledronska kislina kislina Teva Pharma uporablja?
How is Zoledronic acid Teva Pharma used?
Kako se zdravilo Zoledronska kislina kislina Teva Pharma uporablja?
How has Zoledronic acid Teva Pharma been studied?
Kako je bilo zdravilo Zoledronska kislina kislina Teva Pharma raziskano?
This is to be expected and you should not be concerned
To je pričakovano in naj vas ne skrbi.
Your doctor will tell you if this applies to you.
Zdravnik vam bo povedal, ali to velja za vas.
Some may be serious and need medical attention.
Nekateri so lahko resni in zahtevajo zdravniško pomoč.
Date of first authorisation: 22 March 2017
Datum prve odobritve: 22. marec 2017
Maximum effects were generally observed within 6 weeks.
Na splošno so največje učinke opazili v 6 tednih.
However, this difference is not considered to be clinically relevant.
Kljub temu ta razlika ni klinično pomembna.
Efficacy may be decreased
Lahko zmanjša učinkovitost.
These responses were similar to those observed in healthy volunteers aged 50 years and older.
Ti odzivi so bili podobni tistim, ki so jih opazili pri zdravih prostovoljcih, starih 50 let in več.
• Japanese or Korean patients.
• japonskih ali korejskih bolnikih,
These changes generally resolved within 2-6 weeks after discontinuation of treatment.
Te spremembe so na splošno izzvenele 2-6 tednov po prekinitvi zdravljenja.
Antimalarials were allowed.
Antimalariki so bili dovoljeni.
This treatment difference was consistent between the 2 subgroups (Table 16).
Ta razlika med zdravljenjema je bila konsistentna med obema podskupinama (preglednica 16).
Active control (ADA)
kontrolna učinkovina (ADA)
Talk to your doctor if you smoke.
Posvetujte se z zdravnikom, če kadite.
• If your treatment is interrupted, your doctor may decide to restart your treatment.
• Če je vaše zdravljenje prekinjeno, se zdravnik lahko odloči, da ga ponovno začne.
Dose should be maintained.
Odmerek je treba vzdrževati.
Formal studies of the potential effect on human fertility have not been conducted.
Formalnih študij o morebitnih učinkih na plodnost pri človeku niso izvedli.
• who have been exposed to TB,
• ki so bili izpostavljeni TB,
Tell your doctor immediately if you feel unwell.
Nemudoma obvestite zdravnika, če se ne počutite dobro.
OPAL BEYOND had a duration of 6 months.
Preskušanje OPAL BEYOND je trajalo 6 mesecev.
• swelling of the lips, tongue or throat
• otekanje ustnic, jezika ali žrela,
Women were estimated to have 7% lower AUC compared to men.
Ocenjujejo, da je vrednost AUC pri ženskah za 7 % manjša kot pri moških.
Treatment groups (randomisation ratio)
Skupine zdravljenja (razmerje randomizacije)
Your doctor will decide whether you need to have herpes zoster vaccination.
Zdravnik se bo odločil, ali potrebujete cepljenje proti herpesu zostru.
If lab value confirmed by repeat testing within 7 days, dosing should be discontinued.
Če je laboratorijska vrednost potrjena s ponovnim testiranjem v 7 dneh, je treba zdravljenje prekiniti.
Try to take your tablet at the same time every day (one tablet in the morning and one tablet in the evening).
Tableto poskusite vzeti vsak dan ob isti uri (eno tableto zjutraj in eno tableto zvečer).
3 Parallel arms:
3 vzporedne skupine:
N=number of patients in the analysis set.
n = število bolnikov v analizirani skupini.
• with recurrent infections,
• s ponavljajočimi se okužbami,
Additional monitoring tests
Dodatni testi za spremljanje
Tell your doctor as soon as you notice any signs or symptoms of infections.
Zdravnika obvestite takoj, ko opazite kakršnekoli znake ali simptome okužb.
He / she will also evaluate whether your body weight, age, or problems being mobile will affect your risk to develop blood clots.
Ocenil bo, ali vaša telesna masa, starost ali težave z gibanjem vplivajo na vaše tveganje za nastanek krvnih strdkov.
- if you have or had hepatitis B or hepatitis C (viruses that affect the liver).
- če imate ali ste imeli hepatitis B ali hepatitis C (virusa, ki prizadeneta jetra).
There are no adequate and well-controlled studies on the use of tofacitinib in pregnant women.
Ustreznih in dobro nadzorovanih študij uporabe tofacitiniba pri nosečnicah niso izvedli.
The median PsA disease duration was 7.5 years.
Mediano trajanje PsA je bilo 7,5 leta.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Znotraj razvrstitve pogostnosti so neželeni učinki navedeni po padajoči resnosti.
Physical function response and health-related outcomes
Odziv telesne funkcije in izidi, povezani z zdravjem
The median PsA disease duration was 3.8 years.
Mediano trajanje PsA je bilo 3,8 leta.
Pharmacokinetic data up to and including a single dose of 100 mg in healthy volunteers indicate that more than 95% of the administered dose is expected to be eliminated within 24 hours.
Farmakokinetični podatki do vključno enkratnega odmerka 100 mg pri zdravih prostovoljcih kažejo, da se več kot 95 % uporabljenega odmerka predvidoma izloči v 24 urah.
• antibiotics such as rifampicin, used to treat bacterial infections
• antibiotiki, kot je rifampicin, ki se uporablja za zdravljenje bakterijskih okužb,
• Active tuberculosis (TB), serious infections such as sepsis, or opportunistic infections (see section 4.4).
• Aktivna tuberkuloza (TB), resne okužbe, kot je sepsa, ali oportunistične okužbe (glejte poglavje 4.4).
The efficacy results for important endpoints assessed are shown in Table 12.
Rezultati učinkovitosti za pomembne opazovane dogodke, ki so jih ocenjevali, so prikazani v preglednici 12.
Severe (including patients undergoing haemodialysis)
huda (vključno z bolniki, ki prejemajo hemodializo)
- if you have heart problems, high blood pressure, or high cholesterol
- če imate težave s srcem, visok krvni tlak ali zvišano raven holesterola v krvi.
Serious infections in the elderly
Resne okužbe pri starejših
In contrast, tofacitinib has a high degree of selectivity against other kinases in the human genome.
Za razliko od tega ima tofacitinib veliko stopnjo selektivnosti proti drugim kinazam v človeškem genomu.
You should tell your doctor if you are using medicines (taken by mouth) that contain any of the following active substances:
Zdravniku povejte, če uporabljate zdravila (jih jemljete tako, da jih pogoltnete), ki vsebujejo katerokoli izmed naslednjih učinkovin:
No data are available on the secondary transmission of infection by live vaccines to patients receiving tofacitinib.
Ni podatkov o sekundarnem prenosu okužbe z živimi cepivi na bolnike, ki prejemajo tofacitinib.
• Use of combined hormonal contraceptives or hormone replacement therapy
• uporaba kombiniranih hormonskih kontraceptivov ali nadomestne hormonske terapije,
4.1 Therapeutic indication
4.1 Terapevtske indikacije
In addition, safety and efficacy of tofacitinib were assessed in an open-label long-term extension study (OCTAVE Open).
Poleg tega so varnost in učinkovitost tofacitiniba ocenili tudi v odprtem, dolgoročnem podaljšanem preskušanju (OCTAVE Open).
Greater than 2 g/dL decrease or less than 8.0 g/dL (confirmed by repeat testing)
zmanjšanje za več kot 2 g/dl ali vrednost, manjša od 8,0 g/dl (potrjeno s ponovnim testiranjem)
Take your next tablet at the usual time and continue as before.
Naslednjo tableto vzemite ob običajnem času in nadaljujte z jemanjem kot običajno.
The treatment interruption period in clinical studies extended up to 1 year.
Obdobje prekinitve zdravljenja je v kliničnih preskušanjih trajalo največ 1 leto.
This patient subsequently made a robust, though delayed, humoral and cellular response to the vaccine (see section 4.4).
Pri tem bolniku se je pozneje pojavil močan, čeprav zapoznel humoralni in celični odziv na cepivo (glejte poglavje 4.4).
Mon., Tue., Wed., Thu., Fri., Sat., Sun.
pon., tor., sre., čet., pet., sob., ned.
The treatment effect was similar in patients independent of rheumatoid factor status, age, gender, race, or disease status.
Učinek zdravljenja je bil pri bolnikih podoben ne glede na status revmatoidnega faktorja, starost, spol, raso ali stanje bolezni.
Durability of clinical responses
Trajnost kliničnih odzivov
Number of patients treated Total study duration
Število zdravljenih bolnikov Skupno trajanje študije
Tofacitinib should not be initiated in patients with active infections, including localised infections.
Zdravljenja s tofacitinibom se ne sme uvesti pri bolnikih z aktivnimi okužbami, vključno z lokaliziranimi okužbami.
ACR response
Odziv ACR
For patients with Baseline BSA ≥ 3% and PASI > 0.
Za bolnike z izhodiščno BSA ≥ 3 % in PASI > 0.
Maintenance (OCTAVE Sustain)
Vzdrževalno zdravljenje (OCTAVE Sustain)
Dosing should be interrupted until haemoglobin values have normalised.
Odmerjanje je treba prekiniti, dokler se vrednosti hemoglobina ne normalizirajo.
The risk of opportunistic infections is higher in Asian geographic regions (see section 4.8).
Tveganje za oportunistične okužbe je večje v azijskih geografskih regijah (glejte poglavje 4.8).
Tell your doctor if you notice any breathing difficulties.
Obvestite zdravnika, če opazite kakršnekoli težave z dihanjem.
Tofacitinib binds predominantly to albumin and does not appear to bind to 1-acid glycoprotein.
Tofacitinib se veže predvsem na albumin in ni videti, da bi se vezal na 1-kisli glikoprotein.
Your doctor should perform liver tests periodically.
Zdravnik mora občasno opraviti jetrne preiskave.
The safety and benefits of XELJANZ in children or adolescents have not yet been established.
Varnosti in koristi zdravila XELJANZ pri otrocih ali mladostnikih še niso dokazali.
Vaccination with live vaccines should occur at least 2 weeks but preferably 4 weeks prior to initiation of tofacitinib or in accordance with current vaccination guidelines regarding immunomodulatory medicinal products.
Cepljenje z živimi cepivi je treba opraviti najmanj 2 tedna, po možnosti pa 4 tedne pred začetkom zdravljenja s tofacitinibom ali v skladu z veljavnimi smernicami za cepljenje v povezavi z imunomodulatorji.
Time to onset was rapid (as early as week 2 in studies ORAL Solo, ORAL Sync, and ORAL Step) and the magnitude of response continued to improve with duration of treatment.
Čas do odziva je bil kratek (že po 2 tednih v preskušanjih ORAL Solo, ORAL Sync in ORAL Step), stopnja odziva pa se je s trajanjem zdravljenja še izboljševala.
Do not use this medicine if you notice the tablets show visible signs of deterioration (for example, are broken or discoloured).
Ne uporabljajte tega zdravila, če na tabletah opazite vidne znake kvarjenja (na primer, če so poškodovane ali spremenjene barve).
If the history of chickenpox is considered doubtful or unreliable it is recommended to test for antibodies against VZV.
Če je anamneza noric dvomljiva ali nezanesljiva, je priporočljivo opraviti test na protitelesa proti VZV.
Tell your doctor if you notice any painful blisters on your skin.
Obvestite zdravnika, če opazite boleče mehurje na koži.
Patients screened positive for hepatitis B or C were excluded from clinical trials.
Bolnike, pri katerih je bil presejalni test za hepatitis B ali C pozitiven, so izključili iz kliničnih preskušanj.
In addition to this leaflet, your doctor will also give you a Patient Alert Card, which contains important safety information that you need to be aware of before you are given XELJANZ and during treatment with XELJANZ.
Poleg tega navodila za uporabo vam bo zdravnik dal tudi opozorilno kartico za bolnika, ki vsebuje pomembne varnostne informacije, ki jih morate poznati, preden vam dajo zdravilo XELJANZ in med zdravljenjem z zdravilom XELJANZ.
Combination with other therapies
Kombinacija z drugimi zdravili
Nominal p≤0.05;
Nominalna vrednost p ≤ 0,05;
When ANC is greater than 1,000, treatment should be resumed as clinically appropriate.
Ko je ANC večje od 1.000, je treba zdravljenje nadaljevati, kot je klinično primerno.
Keep this Patient Alert Card with you.
To opozorilno kartico imejte vedno pri sebi.
After intravenous administration, the volume of distribution is 87 L. Approximately 40% of circulating tofacitinib is bound to plasma proteins.
Po intravenski uporabi je volumen porazdelitve 87 l. Približno 40 % tofacitiniba v obtoku je vezanega na beljakovine v plazmi.
Possible serious side effects In rare cases, infection may be life-threatening.
Možni resni neželeni učinki V redkih primerih so okužbe lahko življenjsko ogrožajoče.
The number of patients with arthritis mutilans or axial involvement was too small to allow meaningful assessment.
Bolnikov z mutilirajočim artritisom ali aksialno prizadetostjo je bilo premalo, da bi lahko podali relevantno oceno.
*Spontaneous reporting data
* Podatki iz spontanih poročanj.
Evidence of persistence of efficacy with tofacitinib treatment for up to 7 years is also provided from data in the one ongoing and one completed open-label, long-term follow-up studies.
Dokazi o ohranjanju učinkovitosti zdravljenja s tofacitinibom do 7 let izhajajo tudi iz podatkov enega odprtega preskušanja, ki še poteka, in enega že zaključenega odprtega preskušanja dolgoročnega spremljanja.
When ALC is greater than 750, treatment should be resumed as clinically appropriate.
Ko je ALC večje od 750, je treba zdravljenje nadaljevati, kot je klinično primerno.
Physical function and health-related quality of life Improvement in physical functioning was measured by the HAQ-DI.
Telesna funkcija in z zdravjem povezana kakovost življenja Izboljšanje telesne funkcije so merili z HAQ-DI.
Changes in lipid parameters from baseline through the end of the study (6-24 months) in the controlled clinical studies in RA are summarised below:
Spremembe lipidnih parametrov od izhodišča do konca preskušanja (6-24 mesecev) v nadzorovanih kliničnih preskušanjih RA so povzete spodaj:
The carcinogenic potential of tofacitinib was assessed in 6-month rasH2 transgenic mouse carcinogenicity and 2-year rat carcinogenicity studies.
Kancerogeni potencial tofacitiniba so ocenili v 6-mesečnem preskušanju kancerogenosti pri transgenih miših rasH2 in v 2-letnem preskušanju kancerogenosti pri podganah.
Table 14 provides additional information regarding pertinent study design and population characteristics.
Preglednica 14 vsebuje dodatne informacije o ustrezni zasnovi preskušanj in značilnostih populacije.
Elderly patients 80 years of age were estimated to have less than 5% higher AUC relative to the mean age of 55 years.
Ocenjujejo, da je pri starejših bolnikih, starih 80 let, vrednost AUC za manj kot 5 % večja kot v populaciji s povprečno starostjo 55 let.
XELJANZ is used for the treatment of the following inflammatory diseases:
Zdravilo XELJANZ se uporablja za zdravljenje naslednjih vnetnih bolezni:
Benign testicular interstitial (Leydig) cell tumours were observed in rats: benign Leydig cell tumours in rats are not associated with a risk of Leydig cell tumours in humans.
Pri podganah so opazili benigne tumorje intersticijskih (Leydigovih) celic v modih: benigni tumorji Leydigovih celic pri podganah niso povezani s tveganjem za tumorje Leydigovih celic pri človeku.
Table 7 provides information regarding the pertinent study design and population characteristics.
Preglednica 7 vsebuje informacije o ustrezni zasnovi preskušanj in značilnostih populacije.
• Pregnancy and lactation (see section 4.6).
• Nosečnost in dojenje (glejte poglavje 4.6).
This condition is an inflammatory disease of the joints, often accompanied by psoriasis.
To je vnetna bolezen sklepov, ki jo pogosto spremlja psoriaza.
Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).
Tofacitinib je mogoče uporabiti kot monoterapijo v primeru intolerance na MTX ali kadar zdravljenje z MTX ni primerno (glejte poglavji 4.4 in 4.5).
If you notice any of the following serious side effects you need to tell a doctor straight away.
Če opazite kateregakoli izmed naslednjih resnih neželenih učinkov, takoj obvestite zdravnika.
If you do not respond well enough or the medicine is not tolerated, you may be given XELJANZ to reduce the sign and symptoms of active psoriatic arthritis and improve the ability to perform daily activities.
Če se na to zdravilo ne boste dovolj dobro odzvali ali ga ne boste prenašali, vam bodo morda dali zdravilo XELJANZ za zmanjšanje znakov in simptomov aktivnega psoriatičnega artritisa in izboljšanje sposobnosti izvajanja vsakodnevnih dejavnosti.
Risk of infection may be higher with increasing degrees of lymphopenia and consideration should be given to lymphocyte counts when assessing individual patient risk of infection.
Tveganje za okužbo je lahko večje z naraščanjem stopnje limfopenije, zato je treba pri ocenjevanju tveganja za okužbo pri posameznem bolniku upoštevati število limfocitov.
Health-related quality of life was assessed by the Short Form Health Survey (SF-36).
Z zdravjem povezano kakovost življenja so ocenili s kratkim vprašalnikom o zdravju (SF-36 - 36-Item Short Form Health Survey).
Pfizer Europe MA EEIG (as MA holder logo)
Pfizer Europe MA EEIG (kot logo imetnika dovoljenja za promet)
Tofacitinib tablets may be crushed and taken with water.
Tofacitinib tablete lahko zdrobite in vzamete z vodo.
Less than or equal to 2 g/dL decrease and greater than or equal to 9.0 g/dL
Priporočilo zmanjšanje za 2 g/dl ali manj in vrednost, večja od ali enaka 9,0 g/dl
XELJANZ must not be used during pregnancy.
Zdravila XELJANZ ne smete uporabljati med nosečnostjo.
Patients were required to have active plaque psoriasis at the screening visit.
Bolniki so morali imeti aktivno psoriazo v plakih ob presejalnem obisku.
You may also be at higher risk of certain lung problems.
Morda obstaja tudi večje tveganje za nekatere težave s pljuči.
Nominal p<0.001;
nominalna vrednost p < 0,001;
For patients with Baseline score > 0.
Za bolnike z izhodiščno oceno > 0.
If you have active psoriatic arthritis you will be first given another medicine to treat your psoriatic arthritis.
Če imate aktivni psoriatični artritis, vam bodo najprej dali drugo zdravilo, ki ga uporabljamo za zdravljenje psoriatičnega artritisa.